ABERA: Net loss narrowed and vaccine pipeline advanced as new lab and funding boosted operations

About this update from Abera Bioscience Ab

Q2 2024 saw Abera Bioscience improve its financial position, launch a new lab in Uppsala, and advance its vaccine pipeline, supported by UK Vaccine Network funding. Net loss narrowed significantly year-over-year, with continued focus on financing for clinical trials.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Abera Bioscience Ab